# US 2024/0197916 A1 · Compositions and methods for in vivo nuclease-mediated gene targeting for the treatment of genetic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197916 A1
- Document ID: US20240197916A1
- Status: Published application
- Kind: A1
- Application number: 18/556,944
- Filed: 2022-04-27
- Published: 2024-06-20
- Earliest claimed: 2021-04-27
- Assignees: The Trustees of the University of Pennsylvania
- Applicants: The Trustees of the University of Pennsylvania
- Inventors: Lili Wang; James M. Wilson; Anna Tretiakova
- Web page: https://patentgrep.com/patent/US20240197916A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/86: Viral vectors
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/40: Systems of functionally co-operating vectors
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A dual vector system for treating a genetic disorder is provided. The system includes (a) a gene editing vector comprising an expression cassette comprising a nucleic acid sequence encoding a nuclease and regulatory sequences that direct expression of the nuclease in a target cell comprising a PCSK9 gene; and (b) a donor vector comprising a nucleic acid sequence encoding an exogenous product for expression from the PCSK9 locus, wherein the inserted nucleic acid sequence does not encode PCSK9, wherein the system further comprises sequences that direct the nuclease to specifically targets the native PCSK9 gene locus; and wherein the native PCSK9 in the target cell is optionally ablated or reduced post-dosing with the dual vector system.

## Claims

### Claim 1

A system for treating a genetic disorder, the system comprising:
(a) a gene editing vector comprising a nucleic acid sequence encoding a nuclease that targets the PCSK9 gene; and
(b) a donor vector comprising a transgene cassette comprising a nucleic acid sequence encoding a transgene and regulatory sequences that direct expression of the transgene in the target cell, the donor vector further comprising homology-directed recombination (HDR) arms 5′ and 3′ to the transgene cassette, wherein the transgene is not PCSK9.

### Claim 2 (depends on 1)

The system according to claim 1, further comprising regulatory sequences that direct expression of the nuclease in a target cell comprising a PCSK9 gene

### Claim 3 (depends on 1, 2)

The system according to claim 1 or claim 2, wherein the nuclease targets PCSK9 exon 7.

### Claim 4 (depends on 1, 2, 3)

The system according to any one of claims 1 to 3, wherein the nuclease is a meganuclease specific for PCSK9.

### Claim 5 (depends on 4)

The system according to claim 4, wherein the meganuclease is the ARCUS meganuclease.

### Claim 6 (depends on 1, 2)

The system according to claim 1 or 2, wherein the gene editing vector comprises a sequence that encodes a Cas9 flanked by nuclear localization signals.

### Claim 7 (depends on 6)

The system according to claim 6, wherein the gene editing vector further comprises an sgRNA comprising at least 20 nucleotides, which specifically binds to a target site in the PCSK9 gene, said target site being 5′ to a protospacer-adjacent motif (PAM) that is specifically recognized by the Cas9.

### Claim 8 (depends on 6)

The system according to claim 6, wherein the donor vector further comprises an sgRNA comprising an at least 20 nucleotide seed region, wherein the sgRNA specifically binds to a target site in the PCSK9 gene, said target site being 5′ to a protospacer-adjacent motif (PAM) that is specifically recognized by the Cas9.

### Claim 9 (depends on 6, 7, 8)

The system according to any one of claims 6 to 8, further comprising an RNA polymerase promoter.

### Claim 10 (depends on 9)

The system according to claim 9, wherein the RNA polymerase promoter is the U6 promoter.

### Claim 11 (depends on 10)

The system according to claim 10, wherein the U6 promoter is located 5′ of the sgRNA.

### Claim 12 (depends on 7, 8, 9, 10, 11)

The system according to any one of claims 7 to 11, wherein the seed region is 100% complementary to the target site sequence.

### Claim 13 (depends on 7, 8, 9, 10, 11)

The system according to any one of claims 7 to 11, wherein the seed region is less than 100% complementary to the target site sequence.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The system according to any one of claims 1 to 13, wherein the transgene is OTC, PKU, CTLN1, or LDLR.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The system according to any one of claims 1 to 14, wherein at least one of the donor vector and gene editing vector is an adeno-associated viral (AAV) vector, and the AAV vector comprises AAV 5′ ITRs and AAV 3′ ITRs.

### Claim 16 (depends on 15)

The system according to claim 15, wherein the ratio of gene editing AAV vector of (a) to donor AAV vector of (b) is such that donor AAV vector of (b) is in excess of gene editing vector of (a).

### Claim 17

A system for treating a genetic disorder, the system comprising:
(a) a gene editing AAV comprising an AAV capsid and a first vector genome comprising a 5′ ITR, a sequence encoding a meganuclease that targets PCSK9 under control of regulatory sequences that direct expression of the meganuclease in a target cell comprising a PCSK9 gene, and a 3′ ITR; and
(b) a donor AAV vector comprising an AAV capsid and a second vector genome comprising: a 5′ITR, a 5′ homology directed recombination (HDR) arm, a transgene and regulatory sequences that direct expression of the transgene in the target cell, a 3′ HDR arm, and a 3′ ITR.

### Claim 18

A system for treating a genetic disorder, the system comprising:
(a) a gene editing AAV comprising an AAV capsid and a first vector genome comprising a 5′ ITR, a 5′ nuclear localization signal (NLS), a sequence encoding a Cas9 and regulatory sequences that direct expression of the saCas9 in a target cell comprising the PCSK9 gene, a 3′ NLS, and a 3′ ITR; and
(b) a donor AAV vector comprising an AAV capsid and a second vector genome comprising: a 5′ITR, a 5′ homology directed recombination (HDR) arm, a transgene and regulatory sequences that direct expression of the transgene in the target cell, a 3′ HDR arm, a U6 promoter, a sgRNA comprising at least 20 nucleotides that specifically bind to a target site in the PCSK9 gene, said target site being 5′ to a protospacer-adjacent motif (PAM) that is specifically recognized by the Cas9, and a 3′ ITR.

### Claim 19

A system for treating a genetic disorder, the system comprising:
(a) a gene editing AAV vector comprising an AAV capsid and a first vector genome comprising a 5′ ITR, a U6 promoter, a sgRNA comprising at least 20 nucleotides that specifically bind to a target site in the PCSK9 gene, said target site being 5′ to a protospacer-adjacent motif (PAM) that is specifically recognized by the Cas9, a 5′ nuclear localization signal (NLS), a sequence encoding a Cas9 and regulatory sequences that direct expression of the Cas9 in a target cell comprising the PCSK9 gene, a 3′ NLS, and a 3′ ITR; and
(b) a donor AAV vector comprising an AAV capsid and a second vector genome comprising: a 5′ITR, a 5′ homology directed recombination (HDR) arm, a transgene and regulatory sequences that direct expression of the transgene in the target cell, a 3′ HDR arm, and a 3′ ITR.

### Claim 20

A system for treating a genetic disorder, the system comprising:
(a) a gene editing vector comprising:
(i) a lipid nanoparticle;
(ii) a sgRNA comprising at least 20 nucleotides that specifically bind to a target site in the PCSK9 gene, said target site being 5′ to a protospacer-adjacent motif (PAM) that is specifically recognized by a Cas9;
(iii) an mRNA comprising a 5′ nuclear localization signal (NLS), a sequence encoding the Cas9, a 3′ NLS; and
(b) a donor AAV vector comprising an AAV capsid and a second vector genome comprising: a 5′ITR, a 5′ homology directed recombination (HDR) arm, a transgene and regulatory sequences that direct expression of the transgene in the target cell, a 3′ HDR arm, and a 3′ ITR.

### Claim 21 (depends on 17, 18, 19)

The system according to any one of claims 17 to 19, wherein the gene editing AAV vector of (a) and the donor AAV vector of (b) have the same AAV capsid.

### Claim 22 (depends on 21)

The system according to claim 21, wherein the AAV capsid is selected from AAV8, AAV9, rh10, AAV6.2, AAV3B, hu37, rh79, and rh64.

### Claim 23 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The system according to any one of claims 6 to 18, or 18 to 22, wherein Cas9 is selected from Staphylococcus aureus or Streptococcus pyogenes Cas9.

### Claim 24 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The system according to any one of claims 2 to 19, wherein the nuclease is under the control of a tissue-specific promoter.

### Claim 25 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The system according to any one of claims 2 to 19, wherein the nuclease is under the control of a constitutive promoter.

### Claim 26 (depends on 24)

The system according to claim 24, wherein the nuclease is under the control of a liver-specific promoter, optionally a human thyroxin-binding globulin (TBG) promoter, or hybrid liver promoter (HLP).

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method of treating a disorder in humans by co-administering the system according to any one of claims 1 to 26.

### Claim 28

A method of treating a liver metabolic disorder in a neonate subject, the method comprising: co-administering to the subject having a liver metabolic disorder:
(a) a gene editing AAV vector comprising a sequence encoding a nuclease and regulatory sequences that direct expression of the nuclease in a target cell comprising a PCSK9 gene; and
(b) a donor AAV vector comprising a transgene and regulatory sequences that direct expression of the transgene in the target cell, the donor vector further comprising homology-directed recombination (HDR) arms 5′ and 3′ to the transgene cassette.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the gene editing AAV vector of (a) and the donor vector of (b) are delivered essentially simultaneously via the same route.

### Claim 30 (depends on 28, 29)

The method according to claim 28 or claim 29, wherein the gene editing AAV vector of (a) is suspended in a vehicle for injection at a concentration of about 2×1011 GC/mL to about 2×1012 GC/mL.

### Claim 31 (depends on 28, 29)

The method according to claim 28 or claim 29, wherein the AAV targeting vector of (a) is suspended in a vehicle for injection at a concentration of about 2×1012 GC/mL to about 1×1013 GC/mL.

### Claim 32 (depends on 28, 29, 30, 31)

The method according to any one of claims 28 to 31, wherein the liver metabolic disorder is ornithine transcarbamylase.

### Claim 33 (depends on 28, 29, 30, 31)

The method according to any one of claims 28 to 31, wherein the liver metabolic disorder is OTC, FH, citrullinemia type I (CTLN1) or phenylketonuria.

### Claim 34

A system for treating genetic disorders, the system comprising:
(a) a lipid nanoparticle (LNP) comprising a mRNA sequence encoding a nuclease; and
(b) a donor AAV vector comprising a transgene and regulatory sequences which direct its expression in the target cell, the donor vector further comprising a homology-directed recombination (HDR) arms 5′ and 3′ to the transgene.

### Claim 35 (depends on 34)

The system according to claim 34, wherein the nuclease targets the PCSK9 gene.

### Claim 36 (depends on 34)

The system according to claim 34, wherein the nuclease targets PCSK9 exon 7.

### Claim 37 (depends on 34)

The system according to claim 34, wherein the nuclease is a meganuclease specific for PCSK9.

### Claim 38 (depends on 37)

The system according to claim 37, wherein the meganuclease is the ARCUS meganuclease.

### Claim 39 (depends on 34)

The system according to claim 34, wherein the nuclease is a Cas9 nuclease and wherein said LNP comprises an sgRNA.

### Claim 40 (depends on 39)

The system according to claim 39, wherein the Cas9 nuclease is flanked by nuclear localization signals.

### Claim 41 (depends on 39, 40)

The system according to claim 39 or 40, wherein the sgRNA comprises at least 20 nucleotides which specifically bind to a target site in the PCSK9 gene, said target site being 5′ to a protospacer-adjacent motif (PAM) that is specifically recognized by the Cas9.

### Claim 42 (depends on 34, 35, 36, 37, 38, 39, 40, 41)

The system according to any one of claims 34 to 41, further comprising an RNA polymerase promoter.

### Claim 43 (depends on 43)

The system according to claim 43, wherein the RNA polymerase promoter is the U6 promoter.

### Claim 44 (depends on 46)

The system according to claim 46, wherein the U6 promoter is located 5′ of the sgRNA.

### Claim 45 (depends on 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The system according to any one of claims 34 to 44, wherein the sgRNA is 100% complementary to the target site sequence.

### Claim 46 (depends on 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The system according to any one of claims 34 to 44, wherein the sgRNA is less than 100% complementary to the target site sequence.

### Claim 47 (depends on 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The system according to any one of claims 34 to 46, wherein the transgene is a liver-expressed gene.

### Claim 48 (depends on 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The system according to any one of claims 34 to 47, wherein the transgene is selected from OTC, PKU, CTLN1 and FH.

### Claim 49

A system for treating a genetic disorder, the system comprising:
(a) a gene editing vector comprising a nucleic acid sequence encoding a nuclease; and
(b) a donor vector comprising a nucleic acid sequence encoding an exogenous product for expression from the PCSK9 locus, wherein the inserted nucleic acid sequence does not encode PCSK9,
wherein the system further comprises sequences that direct the nuclease to specifically targets the native PCSK9 gene locus; and
wherein the native PCSK9 in the target cell is optionally ablated or reduced post-dosing with the dual vector system.

### Claim 50 (depends on 49)

A method of treating a patient using the system of claim 49, wherein the patient's native PCSK9 expression levels are reduced and wherein the patient expresses the exogenous product.

### Claim 51

An expression cassette comprising the engineered coding sequence of SEQ ID NO: 17, or a sequence sharing at least 90% identity therewith.

### Claim 52 (depends on 51)

The expression cassette according to claim 51, further comprising AAV 5′ and 3′ ITRs.

### Claim 53 (depends on 51, 52)

An AAV vector comprising the expression cassette according to claim 51 or 52.
